The high mobility group type A-2 (HMGA2) transcription factor is involved in proliferation and differentiation, mainly during embryogenesis. Its activated form (HMGA2/T) presents oncogenic activities both in vivo and in vitro. However, its precise role during embryogenesis is unknown. We investigated its role during the commitment of mouse embryonic stem (ES) cells by constructing cell lines expressing either wild type (wt) or HMGA2/T forms of the gene. Following differentiation, control and wt HMGA2 ES cells did not display myotubes; whereas HMGA2/T ES cell lines massively formed contractile myotubes. Furthermore, as opposed to control cells, HMGA2/T ES cells highly expressed the muscle myosin heavy chain (MHC) marker. Interestingly, in experimental conditions inhibitory for myogenesis, we observed a strong expression of MyoD and myogenin in HMGA2/T cells. By contrast, commitment into adipocyte, neuron, and cardiomyocyte lineages was not affected. Teratocarcinomas induced by HMGA2/T ES cell lines presented numerous skeletal muscle-differentiated tissues that were not observed in wt HMGA2 or control tumours. Finally, rapamycin, an inhibitor of the mTOR kinase, downregulated endogenous HMGA-2 expression and inhibited myogenesis. This effect was prevented by overexpression of exogenous HMGA-2. Our results reveal a novel function of HMGA-2 in skeletal muscle differentiation.
Introduction
The architectural transcription factor high mobility group type A-2 (HMGA2) (previously named HMGI-C) regulates gene expression by binding to promoters via three DNA-binding domains in the N-terminus of the protein (Reeves and Beckerbauer, 2001 ). HMGA2 proteins act by inducing conformational changes in the chromatin, thereby facilitating the formation of enhanceosomes on gene promoters. During embryogenesis, the expression of HMGA2 is initially maximal throughout the whole embryo, subsequently restricted to mesenchymal derivatives only, to become virtually undetectable in adult tissues (Zhou et al., 1996; Hirning-Folz et al., 1998) . Chromosomal rearrangements leading to expression of the carboxyl-terminally truncated HMGA2 form (HMGA2/T) have been associated with human benign tumours of mesenchymal origin, such as lipomas and leiomyomas Tallini et al., 2000) . This truncated form can transform NIH3T3 (Fedele et al., 1998) and is thought to be an activated form. Knockout mice for the HMGA2 gene are dwarf, and HMGA2 À/À embryo fibroblasts present a proliferative defect . These animals are sterile because of deficient spermatogenesis (Chieffi et al., 2002) . Conversely, transgenic mice expressing the activated form of HMGA2 are giant, obese (Battista et al., 1999) and develop lymphomas (Baldassarre et al., 2001) . As a result of its effects on adipose tissue, it has been hypothesized that HMGA2 is involved in the proliferation of preadipocyte precursor cells during adipogenesis (Anand and Chada, 2000) . The pronounced and complex phenotypes of both knockout and transgenic HMGA2 animals suggest that HMGA2 is important for the commitment in several cellular lineages. In order to directly test this hypothesis in a homogenous cell system, we investigated the role of HMGA2 in embryonic cells (ES) cell differentiation.
Owing to their in vivo and in vitro pluripotency, mouse ES cells provide a pertinent model for analysing cell commitment to a particular lineage and for studying the molecular events controlling the early stages of differentiation. To achieve differentiation, ES cells have to be cultivated following a complex and precise protocol that, initially, involves culture in suspension. This growth condition induces their aggregation and the formation of embryoid bodies (EB), allowing ES cells to determinate into the three primary germ layers, ectoderm, mesoderm and endoderm. During this step, a treatment with the potent morphogen retinoic acid (RA) orientates ES cells towards certain lineages while inhibiting others. Upon incubation under appropriate culture conditions ES cells can, thereafter, differentiate into a variety of cell types, including skeletal-muscle cells, adipocytes, cardiac cells or neurons (Wobus, 2001) .
We investigated the role of HMGA2 in the commitment of ES cells by constructing cell lines overexpressing either wt or activated forms of this gene. ES cell lines were isolated at the undifferentiated state and analysed for their capacities to give rise to various lineages. Whereas no effect was detected on adipogenesis, cardiomyogenesis or neurogenesis, our results revealed an unsuspected function for HMGA2 in skeletal muscle biology.
Results

Endogenous HMGA2 expression in adult tissues and during ES cell differentiation
Although HMGA2 expression is mainly embryonic (Zhou et al., 1996) , its expression has been detected in testis (Chieffi et al., 2002) and in adipose tissues (Anand and Chada, 2000) of adult mice, suggesting functional links between these tissues and HMGA2. We examined its expression in various adult tissues of mice by RT-PCR. No expression was found in the liver and kidney, but a significant HMGA2 signal was detected in white adipose tissue, testis and, interestingly, in the skeletal muscle ( Figure 1a) . Identical results were found in five different animals. This result suggests that, in addition to its role in adipose tissue and testis, HMGA2 could also play a role in adult muscle biology.
We then followed the HMGA2 endogenous expression during ES cell differentiation (Figure 1b) . The analysis was performed during the EB formation step, between days 0 and 7, and thereafter, between days 8 and 21, when terminal differentiated cells appear. Routinely, cardiomyocytes, by day 10, and myoblasts, by day 15, appear spontaneously (NoRA condition), while an early RA condition treatment, from days 2 to 5, leads to neurons, by day 10, and adipocytes, by day 21, and inhibits both cardiomyogenesis and myogenesis (schematically represented on Figure 1b lower panel). Endogenous HMGA2 expression was barely detectable in undifferentiated ES cells and during the first three days of the differentiation protocol, staying at a low level until day 7. Subsequently, in NoRA condition, the expression peaked between days 7 and 12 (a proliferative period for undifferentiated mesenchymal cells), and thereafter declined to a lower level when various terminally differentiated cell types started appearing (Figures 1b and 2c) , as was similarly found by Vernochet et al. (2002) . This peak was completely inhibited by the RA treatment between days 2 and 5. The HMGA2 expression profile is therefore compatible with the role of HMGA2 between days 4 and 12 of the differentiation process of ES cells, a critical period for the differentiation of these cells. In addition, present in permissive NoRA condition and absent in inhibitory RA condition, the peak of HMGA2 expression correlates with cardiomyogenesis and myogenesis.
Construction of ES cell lines overexpressing HMGA2
To investigate the role of HMGA2 in ES cell commitment, we then constructed ES cells lines overexpressing wt and activated forms of HMGA2 under the control of the ubiquitous and constitutive CAG promoter (Niwa et al., 1991) . Following cotransfection of HMGA2-expressing vectors with a Neo R plasmid into undifferentiated ES cells, and G418 selection, resistant colonies were analysed for the exogenous HMGA2 RNA expression (Figure 2a) . A high HMGA2 expression was found in two cell lines expressing the activated form (clones A2/T20 and A2/T64) and two for the wt form (A2wt1 and A2wt10). Cellular lysates were run on SDS-PAGE gels and HMGA2 proteins analysed by Western blotting; wt and truncated HMGA2 proteins migrate at similar apparent molecular weights of 17 kDa (Reeves and Nissen, 1999) . As opposed to mock and CGR8 ES cells, exogenous wt and truncated HMGA2 proteins were readily detected in HMGA2 ES cell lines (Figure 2b ). We analysed HMGA2 mRNAs throughout the differentiation process and found that the expression of both exogenous wt and activated HMGA2 forms (Figure 2c ). This high level of expression was similar to the level of the endogenous expression observed in NoRA condition during the differentiation process, showing that the exogenous levels comprised physiological ranges (Figure 2c ).
In vitro HMGA2 effects on ES cell differentiation
We investigated the effects of these HMGA2 overexpressions in the commitment of ES cells by cultivating the different cell lines in differentiation medium. No visible difference was noted until day 21. Thereafter, in NoRA condition, whereas control cells or ES cells expressing wt HMGA2 rarely form myotubes (observed in only 10% of the EB), a striking difference appeared in cultures of the two A2/T20 and A2/T64 cell lines: about 50% of EBs spontaneously and massively formed contractile myotubes (Figure 3a and b) . It is noteworthy that while the myotubes observed in control and wt HMGA2 EBs are isolated, myotubes are numerous and organized in networks (see an example in Figure 3a ) in the case of HMGA2/T EBs. To demonstrate the myogenic characteristic of these formations, we performed an immunofluorescence staining against troponin T, a well-known myogenic marker. Whereas control cultures were almost not labelled, the anti-troponin T antibody strongly stained the myotubes observed in HMGA2/T cells ( Figure 3a) . Therefore, in contrast to wt HMGA2, HMGA2/T enhances myogenic differentiation, which leads to myotube network formation. Importantly, unlike control cells, in NoRA myogenic permissive conditions, wt and truncated HMGA2 ES cells highly expressed the skeletal muscle marker (Figure 3c ). These results show that both forms of HMGA2 commit differentiated ES cells towards the myogenic phenotype, but only HMGA2/T is able to push the cells to myotube formation. Skeletal myogenesis is a complex process necessitating expression of the muscle-specific transcription factors Myf5, MyoD and myogenin. These proteins act successively during differentiation at the myoblast stage, which precedes terminal differentiation characterized by myotube formation (Molkentin and Olson, 1996) . To get insights into molecular events underlying the myogenic effect of HMGA2, we analysed the expression of these genes during the differentiation of CGR8 ES cells. In NoRA conditions, which are permissive for myogenesis, Myf5 expression was transitory and peaked between days 2 and 5 (data not shown, see Figure 4a for expression at day 4), reflecting its role during the determination step of myogenesis. MyoD expression is more complex, peaking between days 2 and 5 and reappearing by day 21 (data not shown, see Figure 4a for expression at day 4 and Figure 4b at day 21). This biphasic expression profile is in agreement with the known MyoD function is both determination and terminal differentiation processes. Finally, myogenin appeared by day 15 and stayed at high levels to the end (data not shown, see Figure 4c for expression at day 21). These various expression profiles in ES cells are compatible with known functions in myogenesis described for these factors in other cellular models (Molkentin and Olson, 1996) . Importantly, even if myogenin, a late myoblast marker, was expressed in these conditions, myogenesis was not completely achieved in CGR8 or mock control cells, since no MHC expression and no myotube formation were detected (Figure 3) . We examined whether the expressions of Myf5 and MyoD at day 4 (Figure 4a Expression of the muscle marker myosin heavy chain (MHC) in differentiated control, wt and truncated HMGA2 ES cell lines was analysed by Western blot. Anti-p85 PI3K subunit was used as control these transcription factors. These unknown mechanisms are likely active later on during the differentiation process.
In CGR8 or mock control cells, each of the MyoD, Myf5 and myogenin expressions was inhibited by the RA treatment (Figure 4a , b and c, lanes þ ). While no change was observed in wt HMGA2 cells (Figure 4a and c), the RA-induced inhibitions of MyoD and myogenin, but not that of Myf5, were bypassed in HMGA2/T cells (Figure 4a and c) . Interestingly, this effect was lost when we examined MyoD expression at day 21 (Figure 4b ). Therefore, despite the absence of MHC expression and myotube formation (Figure 3b and c) , HMGA2/T cells conserved a marked myogenic orientation in RA condition inhibitory for myogenesis. This result is evidence of a second specific effect of HMGA2/T on the regulation of myogenesis.
During the same experiments, cell cultures of CGR8, Mock and HMGA2 ES cell lines were precisely characterized for their capacity to differentiate into the other lineages. The percentage of EB with adipocyte outgrowths was roughly similar in the different cell lines (Table 1 for Mock and HMGA2 cells, and not shown for CGR8 cells). This absence of effect was confirmed by measuring the expression of various adipocyte-specific markers. Neither expressions of the adipokine adiponectin (Figure 5a ), the transcription factor PPARg, nor the fatty acid transporter aP2 ( Figure 5b ) were significantly modified in HMGA2 cells compared to control cells. Since adipocyte differentiation was performed in the presence of thiazolidinedione (TZD), a PPARg ligand and powerful adipogenic inducer, which could mask an HMGA2 effect, we also performed all these experiments in the absence of TZD. Similarly, compared to control cells, adipogenesis was not modified in HMGA2 cells under these conditions (data not shown).
Likewise, by day 12, neither neuronal nor cardiomyocyte lineages were significantly affected by the (Table 1) and the expressions of Map2 (Figure 5c ), a neuronal marker, and of Mlc2a (Figure 5d ), a cardiomyocyte marker, were similar in all the cell lines.
Altogether these data show that, in ES cells, HMGA2 favours specifically skeletal myogenesis without affecting the other cell lineages.
Muscle differentiation in teratocarcinomas induced by HMGA/T ES cells
Upon subcutaneous injection in animals ES cells are tumorigenic, inducing teratocarcinoma. These tumours present various differentiated tissues derived from the injected cells. Therefore, we investigated the capacity of the different ES cell lines to differentiate in vivo after Figure 6a , left panels) and, very rarely, mesodermal structures. All the tumours induced by HMGA2/T ES cells, although presenting similar features, specifically showed numerous and large areas of muscle fibres (Figure 6a , right panels), which are never detected in the other tumours. Analysis of the myogenic markers myogenin and desmin showed a much higher expression (4.5-9-fold) in teratocarcinomas induced by HMGA2/T cells than in control or wt HMGA2 cells (Figure 6b and c), confirming the histological analysis.
In parallel, in the same tumours, PPARg ( Figure 6d ) and adiponectin ( Figure 6e ) expressions were not modified. Therefore, the muscle orientation of HMGA2/T ES cells detected in vitro was also evidenced in vivo.
Inhibition of endogenous HMGA2 expression affects myogenesis in ES cells
A role for HMGA2 in myogenesis has been also suggested by works on the tuberus sclerosis 2 (TSC2) tumour suppressor gene, a negative regulator of the mammalian target of the rapamycin kinase (mTOR) pathway. Indeed, as a result of a mutation in TSC2, aberrant expression of the HMGA2 gene is found in spontaneous leiomyomas developed by Eker rats (Gao et al., 2002; Hunter et al., 2002) . In these tumours of smooth muscle origin, an upregulation of mTOR pathway led to upregulation of HMGA2 expression. Therefore, it is possible that the mTOR-induced regulations of HMGA2 expression and myogenesis are causally linked. In order to verify this hypothesis, we investigated the effects of rapamycin, a specific inhibitor of the mTOR kinase, on HMGA2 expression and myogenesis of ES cells. We found that rapamycin treatment of control EB, between days 7 and 12 of the differentiation process, strongly inhibited the peak of HMGA2 expression observed during this period ( Figure 7a ) and reduced myogenin expression by 60% at day 21 (Figure 7b) . Importantly, rapamycin, between days 7 and 12, did not inhibit myogenin expression in EB expressing a wt or truncated form of HMGA2 ( Figure 7c ) and did not affect myotube formation in HMGA2/T EBs (Figure 7d ). These results confirm the important functions of both forms, wt and truncated, of HMGA2 in myogenic differentiation.
Discussion
The pronounced and complex phenotypes of both knockout and transgenic HMGA2 animals suggest that HMGA2 is crucial during mouse embryonic development Battista et al., 1999) . In order to directly test this hypothesis in a homogenous cell system, we investigated the role of HMGA2 in ES cell commitment by constructing cell lines overexpressing either wt or activated forms of this gene. ES cell lines were isolated at the undifferentiated state and analysed for their capacities to give rise to various lineages. Whereas no effect was detected on adipogenesis, cardiomyogenesis or neurogenesis, our results revealed an unsuspected function of HMGA2 in skeletal muscle biology.
Myogenesis is a complex stepwise process involving successive expression of, initially, Myf5 and MyoD muscle-specific transcription factors and subsequently myogenin, and later on the appearance of the MHC marker and myotube formation (Molkentin and Olson, 1996) . In myogenic permissive NoRA condition, the myogenesis of CGR8 ES cells is only partial, limited to myogenin expression; myotube formation and MHC expression are barely detected. Surprisingly, compared to CGR8 or mock control cells, we found that Figure 7 The mTOR kinase regulates both HMGA-2 expression and myogenesis during ES cell differentiation. HMGA-2 (a) and myogenin (b) expressions in CGR8 cells were analysed by quantitative RT-PCR at days 7, 10 and 12 and at day 21, of the differentiation protocol with or without rapamycin. HMGA2 signals were normalized to 1 for day 7 and myogenin signals to 100 for the NoRA condition at day 21. A2wt1 and A2/T20 cells were treated without RA with (RAPA) or without (Con) rapamycin and analysed for myogenin expression at day 21 by quantitative RT-PCR (c) and myotube formation (d). Signals were normalized to 100 for control treated cells. Mean values of three independent experiments are given myogenesis of cells overexpressing wt HMGA2 or HMGA2/T was profoundly perturbed. First, we found that the MHC skeletal muscle marker is strongly expressed in both wt and HMGA2/T ES cells and, secondly, that HMGA2/T ES cells spontaneously form contractile myotubes. Therefore, HMGA2 allows ES cells to differentiate into the myogenic lineage beyond myogenin expression. As a result of the link between HMGA2 and cell proliferation , one can hypothesize that the myogenic effect of HMGA2 could be due to a deregulation of proliferation of muscle precursor cells. We first checked a possible general effect on proliferation by analysing the growth curves of EB during the first steps of differentiation, between days 0 and 7, and found no change in proliferation of the different cell lines (data not shown). Likewise, the expression levels of the major muscle regulators MyoD, Myf5 and myogenin were not modified throughout the myogenic differentiation process of these cells, suggesting that the number of myoblasts in EB is not affected by HMGA2 overexpressions. Furthermore, since the late expression of MyoD and myogenin are not changed in HMGA2 cells, the myotube formation observed in these cells does not involve deregulation of these genes. Still, it should be interesting to test whether the intrinsic activity of these myogenic factors is different in HMGA2 cells compared to control cells. Alternatively, the underlying molecular mechanism of the HMGA2 effect can take place later during the differentiation process.
Compared to control and HMGA2/T cells, ES cell lines overexpressing the wt form present an intermediate myogenic commitment. These variable effects are in agreement with the known properties of the two proteins. For example, overexpression of the activated form, and not the wt form, confers oncogenic properties in vitro to recipient cells and in vivo to transgenic animals, and HMGA2/T, but not wt, transgenic animals presented a giant phenotype (Fedele et al., 1998; Battista et al., 1999) . The precise molecular mechanisms involved in these differential effects are unknown. However, a recent study (Noro et al., 2003) demonstrated that the absence of the C-terminal tail alters HMGA2/DNA complexes in a subset of DNA sequences. Whether the activated form regulates a subset of target genes involved in myogenesis differently from the wt form needs to be investigated.
Myotube formation of HMGA2/T cells was inhibited in RA conditions, indicating either that RA inhibits key events of myogenesis independently of HMGA2/T, or the other RA-induced cell lineages themselves exert inhibitory effects on myogenesis. Interestingly, as opposed to control cells, expression of the skeletal muscle specific transcription factors MyoD and myogenin was maintained in RA-treated HMGA2/T cells. These results evidence a second independent myogenic effect of HMGA2/T, showing that the role of HMGA2 in the control of myogenesis is not restricted to terminal differentiation but can be evidenced early on in the regulation of expression of the myogenic specific transcription factors.
We found that rapamycin inhibited, between days 7 and 12, both the peak of HMGA2 expression observed during this period and the commitment of ES cells into the myogenic lineage. Moreover, this effect was prevented in ES cell lines overexpressing either wt or truncated exogenous HMGA-2. These results demonstrate a causative role between the peak of endogenous HMGA2 expression and myogenesis in ES cells and show that the mTOR pathway is a modulator of this HMGA2 function. Interestingly, the knockout of S6 kinases, downstream effectors of mTOR, leads to mice of small size (Pende et al., 2004) , which could be related to the phenotype of the HMGA2 knockout mice. The molecular mechanisms underlying the mTOR-induced regulation of HMGA2 gene expression and myogenesis need to be determined.
Although some works evidenced a potential link between HMGA2 and smooth or cardiac muscle biology (Anisimov et al., 2002; Hunter et al., 2002) , our in vitro data are the first to support a direct role of this gene in myogenesis. Moreover, this link is strengthened by in vivo analysis. Whereas control ES cells produced tumours with a majority of immature tissues, teratocarcinomas of HMGA2/T overexpressing cell lines presented numerous differentiated muscle tissues.
In conclusion, we showed that HMGA2/T affects both in vivo as well as in vitro myogenesis. In addition to its documented role in cell proliferation of fibroblasts and in spermatogenesis (Chieffi et al., 2002) , our results show that HMGA2 has an important function in skeletal muscle differentiation. The latter property is reminiscent to the property of another oncogenic transcription factor, Ski, which is also involved in skeletal muscle differentiation (Colmenares and Stavnezer, 1989) . Whether these two nuclear proteins act in parallel or synergistically or have common targets needs further investigation.
Material and methods
Cell culture and differentiation
Mouse ES cells CGR8 were induced to differentiate as described previously in Bost et al. (2002) . Briefly, cells were cultivated in suspension without LIF for 2 days, then EB were treated or not, from days 2 to 5, with 0.1 mM all-trans RA (Sigma, St Louis, MI, USA), and, then, from days 7 to 21, plated and treated with 85 nM insulin (Lilly, Paris, France), 2 nM 3,3 0 ,5-tri-iodothyronine (Sigma) and 10 mM TZD. For mTOR inhibition, 40 nm rapamycin (Calbiochem Bioscience, La Jolla, CA, USA) was added to the culture media, which was renewed every day between days 7 and 12 of the differentiation protocol. Each EB was examined for cardiomyocytes or neurons at day 12, adipocyte colonies at day 21 (Bost et al., 2002) and myotubes at day 26.
HMGA2-expressing vectors and generation of ES Cell lines
The HMGA2 cDNAs were generated by RT-PCR from proliferating 3T3-L1 preadipocytes. wt HMGA2 primers and PCR conditions were as described in Zhou et al. (1996) . For the truncated form (HMGA2/T), sense primer C1 (Zhou et al., 1996) , incorporating the start codon of HMGA2 mRNA was used with the antisense primer CT: (5 0 -GGCGGCCGCCTAC CATTTCCTAGGTCT-3 0 ), including a stop codon. Same PCR conditions were used for the wt and the truncated forms. Amplified cDNA fragments were cloned into the TA Cloning Vector (Invitrogen, San Diego, CA, USA), and subcloned downstream of the CAG promoter (Niwa et al., 1991) to generate the HMGA2 (wt or /T)-expressing vectors; coding sequences were confirmed by sequence analysis.
The CGR8 ES cells were co-transfected with pCAG empty vector, pCAG-HMGA2, or pCAG-HMGA2/T and pGKneo R using FuGene (Roche, Branchburg, USA), according to the manufacturer's protocol. Cells were selected using 200 mg/ml G418 (Life Technologies) for 10 days and individual resistant colonies were isolated and expanded for further analysis.
Protein analysis
In all, 50 mg of whole-cell protein extract was resolved by SDS/PAGE on a 8% (w/v) polyacrylamide gel, transferred onto polyvinylidene difluoride membrane. Membranes were blocked in 1% BSA in TBS-0.1% Tween for 1 h at room temperature and blotted for total sarcomeric MHC (MF20 antibody, Developmental Studies Hybridoma Bank, Iowa City, IA, USA), dilution 1/1000, or p85 subunit of PI3K (UBI, Charlottesville, VA, USA), dilution 1/1000. HMGA proteins were isolated from nuclei using salt extraction buffer and made soluble in 5% (w/v) perchloric acid, as previously described (Reeves and Nissen, 1999) , resolved by SDS/PAGE on a 15% (w/v) polyacrylamide gel, and blotted with anti-HMGA2 antibody (Babco, Richmond, CA, USA), dilution 1/1000, or anti-Histone H1 (FL-219, sc-10806 antibody, Santa Cruz Biotechnology), dilution 1/1000.
Immunofluorescence staining
EBs were fixed in 4% paraformaldehyde for 20 min at 41C, permeabilized in PBS-0.1% Triton X-100 for 15 min at 41C, incubated with monoclonal antitroponin T antibody (CT3; Developmental Studies Hybridoma Bank) at 6 mg/ml, in PBS-1% BSA overnight at 41C, washed and incubated with a secondary FITC-conjugated antibody for 1 h at room temperature.
RNA analysis
Total RNA was extracted using Trizol reagent (Life Technologies) and 15 mg per lane was blotted onto Biotrans nylon membranes (ICN, Costa Mesa, CA, USA), cross-linked under UV and hybridized with radiolabelled cDNA probes. Hybridization signals were quantified using Molecular Dynamics Phosphorimager and Image Quant software.
RT-PCR analysis was performed by preparing cDNAs from 1 mg of total RNA using MMLV reverse transcriptase (Advantage RT-PCR kit, Clontech) and PCR was performed using puReTaq Ready-To-Go PCR beads (Amersham, Biosciences, England, UK). MyoD1 primers were: forward Quantitative PCR analysis was performed with the ABI Prism 7000 (Applied Biosystem) and SYBR Green reagent (Eurogentec, Seraing, Belgium) for adiponectin or PPARg or TaqMan Universal PCR Master Mix (Roche) for myogenin, desmin and HMGA2, according to the manufacturer's protocol. cDNAs were amplified using the following PCR conditions: 10 min at 951C, 40 cycles: 15 s at 941C, 30 s at 601C and 1 min at 721C. 36B4 was used as internal control.
Induction of teratocarcimomas and histological analysis of tumours
ES cells were trypsinized and washed, and 5 Â 10 6 cells resuspended in 200 ml of PBS were injected subcutaneously into both sides of the back of syngenic 6-week-old 129/Sv female mice. At 5 weeks following injection, tumours were surgically excised, fixed in formalin, paraffin-embedded, and 5 mm thick sections were analysed and photographed after hematoxylin-eosin staining.
